Oncternal Therapeutics, Inc is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Oncternal Therapeutics employs 12 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Oncternal Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ONCT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Oncternal Therapeutics stock price (NASDAQ: ONCT)Use our graph to track the performance of ONCT stocks over time.
Oncternal Therapeutics shares at a glance
|Latest market close||$5.69|
|52-week range||$1.49 - $10.56|
|50-day moving average||$4.90|
|200-day moving average||$6.07|
|Wall St. target price||$15.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.81|
Buy Oncternal Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Oncternal Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Oncternal Therapeutics price performance over time
|1 week (2021-07-12)||N/A|
|1 month (2021-06-23)||9.42%|
|3 months (2021-04-19)||N/A|
|6 months (2021-01-19)||N/A|
|1 year (2020-07-19)||N/A|
|2 years (2019-07-19)||N/A|
|3 years (2018-07-19)||N/A|
|5 years (2016-07-19)||N/A|
Oncternal Therapeutics financials
|Revenue TTM||$3.5 million|
|Gross profit TTM||$-9,169,000|
|Return on assets TTM||-17.78%|
|Return on equity TTM||-31.06%|
|Market capitalisation||$212.3 million|
TTM: trailing 12 months
Shorting Oncternal Therapeutics shares
There are currently 2.7 million Oncternal Therapeutics shares held short by investors – that's known as Oncternal Therapeutics's "short interest". This figure is 116% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Oncternal Therapeutics shares can be evaluated.
Oncternal Therapeutics's "short interest ratio" (SIR)
Oncternal Therapeutics's "short interest ratio" (SIR) is the quantity of Oncternal Therapeutics shares currently shorted divided by the average quantity of Oncternal Therapeutics shares traded daily (recently around 1.3 million). Oncternal Therapeutics's SIR currently stands at 2.18. In other words for every 100,000 Oncternal Therapeutics shares traded daily on the market, roughly 2180 shares are currently held short.
However Oncternal Therapeutics's short interest can also be evaluated against the total number of Oncternal Therapeutics shares, or, against the total number of tradable Oncternal Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncternal Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Oncternal Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0619% of the tradable shares (for every 100,000 tradable Oncternal Therapeutics shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncternal Therapeutics.
Find out more about how you can short Oncternal Therapeutics stock.
Oncternal Therapeutics share dividends
We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.
Have Oncternal Therapeutics's shares ever split?
Oncternal Therapeutics's shares were split on a 1:7 basis on 9 June 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.
Oncternal Therapeutics share price volatility
Over the last 12 months, Oncternal Therapeutics's shares have ranged in value from as little as $1.49 up to $10.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncternal Therapeutics's is 1.5487. This would suggest that Oncternal Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncternal Therapeutics overview
Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.
Stocks similar to Oncternal Therapeutics
Oncternal Therapeutics in the news
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Frequently asked questionsWhat percentage of Oncternal Therapeutics is owned by insiders or institutions?
Currently 11.822% of Oncternal Therapeutics shares are held by insiders and 25.161% by institutions. How many people work for Oncternal Therapeutics?
Latest data suggests 12 work at Oncternal Therapeutics. When does the fiscal year end for Oncternal Therapeutics?
Oncternal Therapeutics's fiscal year ends in December. Where is Oncternal Therapeutics based?
Oncternal Therapeutics's address is: 12230 El Camino Real, San Diego, CA, United States, 92130 What is Oncternal Therapeutics's ISIN number?
Oncternal Therapeutics's international securities identification number is: US68236P1075 What is Oncternal Therapeutics's CUSIP number?
Oncternal Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40052B108
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert